INSM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the investor's long-term strategy and beginner-level knowledge, Insmed Inc (INSM) is a good buy. The company's strong revenue growth, positive analyst sentiment, and potential for long-term upside with its Brinsupri launch make it a solid investment opportunity. Despite short-term technical weakness, the long-term outlook aligns well with the investor's goals.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 31.835, and moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 144.033, which could act as a potential floor.
Strong revenue growth of 152.62% YoY in Q4
Positive analyst sentiment with multiple buy and outperform ratings and price targets ranging from $157 to $
Brinsupri launch guidance for FY26 of at least $1B in sales, indicating strong future potential.
Gross margin improvement to 82.51%, up 11.88% YoY.
Net income remains negative, though losses have narrowed YoY.
Technical indicators show short-term bearish momentum.
No recent significant insider or hedge fund activity to support bullish sentiment.
In Q4 2025, revenue increased by 152.62% YoY to $263.84M, net income improved by 39.46% YoY to -$328.49M, and EPS increased by 17.56% YoY to -1.54. Gross margin rose to 82.51%, reflecting operational efficiency improvements.
Analysts are broadly positive on INSM, with multiple buy and outperform ratings. Price targets range from $157 to $231, with the majority of analysts highlighting the strong potential of Brinsupri and other pipeline developments as key drivers for long-term growth.
